- CLN-PXT3003-06_PREMIER: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)
Acronym |
CLN-PXT3003-06_PREMIER |
Intervention | PXT3003 |
Principal investigator | Giorgia Querin |
Sponsor | Pharnext |
Study status | Ongoing |
Recruitment status | Completed |
Population | Adult |
+ infos on clinical trials.gov |